ArticleBMC public health2015
A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.
Article in BMC public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Cost-effectiveness of latent tuberculosis infection testing and preventive treatment among TB contacts in China: a Markov model.BMC health services research · 2026Article
- Cost-benefit analysis of pre-entry tuberculosis screening for incoming migrants to Japan: a focus on Nepalese migrants.Health economics review · 2025Article
- Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.The American journal of tropical medicine and hygiene · 2024Article
- Systematic review of the economic impact of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection compared with tuberculin skin test and interferon-gamma release assays.PLOS global public health · 2024Article
- Overseas Treatment of Latent Tuberculosis Infection in US-Bound Immigrants.Emerging infectious diseases · 2022Article
- Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.American journal of respiratory and critical care medicine · 2020Article
- Tuberculosis among Newly Arrived Immigrants and Refugees in the United States.Annals of the American Thoracic Society · 2020Article
- Tuberculosis treatment outcomes of non-citizen migrants: Israel compared to other high-income countries.Israel journal of health policy research · 2020Review
- Review
- Cost analysis of measles in refugees arriving at Los Angeles International Airport from Malaysia.Human vaccines & immunotherapeutics · 2017Article
- A Cost-benefit Analysis of a Proposed Immigrant Latent Tuberculosis Infection Screening Program for Cyprus.Materia socio-medica · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored the effect of screening and treatment of refugees for latent tuberculosis infection (LTBI) before entrance to the United States as a strategy for reducing active tuberculosis (TB). The purpose of this study was to estimate the costs and benefits of LTBI screening and treatment in United States bound refugees prior to arrival.
methodsCosts were included for foreign and domestic LTBI screening and treatment and the domestic treatment of active TB. A decision tree with multiple Markov nodes was developed to determine the total costs and number of active TB cases that occurred in refugee populations that tested 55, 35, and 20 % tuberculin skin test positive under two models: no overseas LTBI screening and overseas LTBI screening and treatment. For this analysis, refugees that tested 55, 35, and 20 % tuberculin skin test positive were divided into high, moderate, and low LTBI prevalence categories to denote their prevalence of LTBI relative to other refugee populations.
resultsFor a hypothetical 1-year cohort of 100,000 refugees arriving in the United States from regions with high, moderate, and low LTBI prevalence, implementation of overseas screening would be expected to prevent 440, 220, and 57 active TB cases in the United States during the first 20 years after arrival. The cost savings associated with treatment of these averted cases would offset the cost of LTBI screening and treatment for refugees from countries with high (net cost-saving: $4.9 million) and moderate (net cost-saving: $1.6 million) LTBI prevalence. For low LTBI prevalence populations, LTBI screening and treatment exceed expected future TB treatment cost savings (net cost of $780,000).
conclusionsImplementing LTBI screening and treatment for United States bound refugees from countries with high or moderate LTBI prevalence would potentially save millions of dollars and contribute to United States TB elimination goals. These estimates are conservative since secondary transmission from tuberculosis cases in the United States was not considered in the model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.